Galectin Therapeutics Inc. cash flow to debt ratio of -17.85% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Galectin Therapeutics Inc.'s free cash flow has increased -42.84% from $-41.77M last year to $-23.88M, signaling increasing performance

Galectin Therapeutics Inc.'s debt to equity ratio is -1.04, signaling that the company spent its equity and risk bankruptcy.

Galectin Therapeutics Inc.'s debt to equity ratio is -1.04, signaling that the company spent its equity and risk bankruptcy.

Galectin Therapeutics Inc. has negative EBITDA, making leverage ratio unreliable

Galectin Therapeutics Inc.'s interest coverage ratio is -2.15, which means that the company struggles to meet interest obligations, signaling financial risk.

Galectin Therapeutics Inc. has insufficient data to evaluate this check.

Galectin Therapeutics Inc.'s short-term assets of $19.44M exceed its short-term liabilities of $8.03M

Galectin Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Galectin Therapeutics Inc.'s return on equity of 21.05%, is higher than 15.00%, indicating good performance

Galectin Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Galectin Therapeutics Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Galectin Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Galectin Therapeutics Inc. has negative free cash flow, indicating cash burn

Galectin Therapeutics Inc.'s yearly earnings has increased -34.46% since last year from $-47.05M to $-30.84M, signaling increasing performance

Galectin Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -192.30% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Galectin Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Galectin Therapeutics Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Galectin Therapeutics Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Galectin Therapeutics Inc. has insufficient data to evaluate this check.

Galectin Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Galectin Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Galectin Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Galectin Therapeutics Inc. has insufficient data to evaluate this check.

Galectin Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Galectin Therapeutics Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Galectin Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue